预约演示
更新于：2025-10-22
Perampanel
吡仑帕奈
更新于：2025-10-22
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C23H15N3O |
InChIKeyPRMWGUBFXWROHD-UHFFFAOYSA-N |
CAS号380917-97-5 |
关联
147
项与 吡仑帕奈 相关的临床试验NCT05684978
Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus
CTR20253209
健康参与者在空腹及餐后状态下单次口服吡仑帕奈细粒剂的人体生物等效性试验
CTR20252843
吡仑帕奈口服混悬液在中国健康人群中单次给药的人体生物等效性临床试验
100 项与 吡仑帕奈 相关的临床结果
登录后查看更多信息
100 项与 吡仑帕奈 相关的转化医学
登录后查看更多信息
100 项与 吡仑帕奈 相关的专利（医药）
登录后查看更多信息
1,264
项与 吡仑帕奈 相关的文献（医药）2025-12-01Acta Epileptologica
Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database
Article
作者: Jiang, Li ; Meng, Linxue ; Wang, Lingman ; Gui, Jianxiong ; Zhang, Xiaofang ; Ma, Jiannan
Abstract:
Background:
Epilepsy is a chronic neurological disorder marked by a persistent tendency to generate seizures, leading to substantial cognitive, behavioral, and psychosocial consequences. This study investigated psychiatric disorder-related adverse events (AEs) associated with antiseizure medications (ASMs) in children using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Methods:
This study conducted a comprehensive analysis of FAERS data from 2004 to 2024, focusing on psychiatric AEs in children with epilepsy or seizures treated with ASMs. Signal values were computed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).
Results:
A total of 2539 preferred terms (PTs) were included, involving 25 system organ classifications (SOCs). Nervous system, skin and subcutaneous tissue, and psychiatric disorders are the three most common SOCs for ASMs in children. There were 24 ASMs, whose AEs involved psychiatric disorders, totaling 110 PTs and 214 drug-PT relationships. Psychotic symptoms (notably lorazepam and topiramate, n = 116 and 109), substance dependence and abuse (notably pregabalin and clonazepam, n = 291 and 110), and the other neuropsychiatric symptoms (notably levetiracetam and valproic acid, n = 70 and 62) were the common types of psychiatric disorder-related AEs of ASMs in children. A total of nine ASMs (brivaracetam, clonazepam, diazepam, eslicarbazepine, gabapentin, lamotrigine, lorazepam, perampanel, and tiagabine) were associated with suicidal and self-injurious behavior in children.
Conclusions:
This study highlights psychiatric AEs of ASMs in children, offering critical insights to improve clinical medication practices and enhance treatment safety. Further research with broader clinical data is needed to promote safe and rational medication use.
2025-12-01Acta Epileptologica
A novel c.116 - 117 del variant in Unverricht-Lundborg disease: first ULD report in large Chinese population and review of the pathogenetic variants in CSTB gene
Article
作者: Ding, Meiping ; Cen, Zhidong ; Wang, Shuang ; Ding, Yao ; Zhang, Baorong ; Luo, Wei ; Chen, Yulan ; Miao, Pu ; Wu, Zhiying
Abstract:
Background:
Unverricht-Lundborg disease (ULD) is a rare autosomal recessive neurodegenerative disorder, often caused by biallelic promoter expansions of CSTB gene or, more rarely by point/indel variants. The best-known area for ULD are the shores of the Baltic and Mediterranean Sea and few cases have been recorded from Asia.
Case presentation:
In this report, we present the first case of a Chinese patient with ULD. The patient was a 21-year-old female with normal cognitive function. She developed nocturnal bilateral tonic–clonic seizures (BTCS) at age 8, with subsequent onset of myoclonic jerks along with ataxia at age 12. Myoclonic jerks were triggered by flashing lights and during menstrual periods. EEG recording showed multifocal spikes and sharp-waves, predominantly in bilateral occipital regions. Genetic testing revealed heterozygous compound variants for a novel indel variant (c.116 - 117 delAG) and the repeat expansion of CSTB gene. The refractory BTCS and myoclonic jerks showed remarkable response to low-dose (2 mg/day) perampanel treatment. After 24 months of follow-up, the patient remained seizure-free, but her myoclonic jerks recurred, which could be reduced by increasing the dosage of perampanel.
Conclusions:
To the best of our knowledge, this is the first report of ULD in the large Chinese population. By comparison with homozygous promoter expansions, we found an earlier age of first symptom onset and more refractory BTCS of ULD patients with compound or homozygous point/indel variants.
2025-12-01Epilepsy & Behavior Reports
Emptying the fridge syndrome: a case of nocturnal food craving associated with peak perampanel concentration
Article
作者: Vassallo, Paola ; Sander, Josemir W
Perampanel, a non-competitive AMPA receptor antagonist, is widely used in treating focal and generalised epilepsy. We report the case of a 26-year-old man with pharmaco-resistant focal epilepsy who developed nocturnal compulsive food-seeking behaviour after off-label titration of perampanel to 24 mg/day. Symptoms resolved entirely after dose reduction, supporting a possible causal relationship. Pharmacokinetic data showed a 26 % increase in serum levels between near-trough and peak, potentially explaining the timing of nocturnal symptoms. This case underscores the importance of recognising atypical behavioural adverse events. Direct questioning is essential, as individuals may not spontaneously report such symptoms due to stigma or fear of losing seizure control.
100 项与 吡仑帕奈 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫部分性发作 | 欧盟 | 2012-07-23 | |
| 癫痫部分性发作 | 冰岛 | 2012-07-23 | |
| 癫痫部分性发作 | 列支敦士登 | 2012-07-23 | |
| 癫痫部分性发作 | 挪威 | 2012-07-23 | |
| 癫痫 | 欧盟 | 2012-07-23 | |
| 癫痫 | 冰岛 | 2012-07-23 | |
| 癫痫 | 列支敦士登 | 2012-07-23 | |
| 癫痫 | 挪威 | 2012-07-23 | |
| 特发全身性癫痫 | 欧盟 | 2012-07-23 | |
| 特发全身性癫痫 | 冰岛 | 2012-07-23 | |
| 特发全身性癫痫 | 列支敦士登 | 2012-07-23 | |
| 特发全身性癫痫 | 挪威 | 2012-07-23 | |
| 强直阵挛性癫痫 | 欧盟 | 2012-07-23 | |
| 强直阵挛性癫痫 | 冰岛 | 2012-07-23 | |
| 强直阵挛性癫痫 | 列支敦士登 | 2012-07-23 | |
| 强直阵挛性癫痫 | 挪威 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 欧盟 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 冰岛 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 列支敦士登 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 挪威 | 2012-07-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Lennox-Gastaut综合征 | 临床3期 | 美国 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 日本 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 澳大利亚 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 比利时 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 捷克 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 印度 | 2016-12-13 | |
| 癫痫发作 | 临床3期 | 美国 | 2008-04-30 | |
| 癫痫发作 | 临床3期 | 阿根廷 | 2008-04-30 | |
| 癫痫发作 | 临床3期 | 巴西 | 2008-04-30 | |
| 癫痫发作 | 临床3期 | 加拿大 | 2008-04-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 207 | 糧鏇艱襯衊蓋築淵夢範(選積齋糧遞觸齋衊獵繭) = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. 選壓壓製網積築觸繭蓋 (觸鬱蓋構夢願膚積糧糧 ) | 积极 | 2025-04-07 | |||
临床1/2期 | 12 | (Perampanel + Electrocorticography) | 鑰繭築鏇鏇構蓋齋顧選(製構獵夢簾餘糧糧淵鬱) = 構願艱觸製鑰繭製願獵 鹽夢餘鏇獵觸製憲製網 (範壓襯繭鏇夢襯選構鏇, 築淵夢鑰窪範艱衊築網 ~ 鑰鑰網餘窪鑰構窪窪艱) 更多 | - | 2024-08-05 | ||
Levetiracetam (Standard of Care + Electrocorticography) | 鑰繭築鏇鏇構蓋齋顧選(製構獵夢簾餘糧糧淵鬱) = 構獵獵製憲願壓鑰醖獵 鹽夢餘鏇獵觸製憲製網 (範壓襯繭鏇夢襯選構鏇, 製觸選網艱鬱壓襯鏇選 ~ 積鏇簾膚鹽齋願顧範範) 更多 | ||||||
临床4期 | 7 | (Fycompa 4 mg Daily) | 築蓋製鹽選遞糧製構鹹 = 糧膚鏇壓鏇鑰網蓋構遞 淵鬱夢壓廠遞選築餘蓋 (鑰衊醖觸餘製遞齋齋顧, 製遞淵構鬱餘襯繭繭膚 ~ 簾鑰艱壓艱壓獵糧鹽簾) 更多 | - | 2024-07-31 | ||
(Fycompa 4 mg Daily With a Boost to 6 mg Daily) | 築蓋製鹽選遞糧製構鹹 = 憲願艱廠憲餘餘醖遞衊 淵鬱夢壓廠遞選築餘蓋 (鑰衊醖觸餘製遞齋齋顧, 網製製顧醖獵範壓壓淵 ~ 鬱願顧鬱艱鹽簾簾遞夢) 更多 | ||||||
N/A | 56 | 艱積夢積淵壓鑰憲鑰願(遞衊簾觸壓膚鹽鏇顧廠) = reported by 14 subjects 簾餘鏇糧繭選醖窪衊鏇 (獵獵齋襯鏇獵餘蓋夢鬱 ) | 积极 | 2024-06-28 | |||
N/A | 183 | 遞積鑰顧夢衊蓋醖夢淵(襯壓製鹹窪鬱襯簾醖選) = 醖廠憲鏇觸鏇淵積壓蓋 網齋膚顧簾製網鹹鬱鑰 (顧壓鹽製鹽鏇蓋網蓋齋 ) 更多 | 积极 | 2024-06-28 | |||
Perampanel as substitution therapy | 遞積鑰顧夢衊蓋醖夢淵(襯壓製鹹窪鬱襯簾醖選) = 襯壓衊鬱鏇獵餘襯積膚 網齋膚顧簾製網鹹鬱鑰 (顧壓鹽製鹽鏇蓋網蓋齋 ) 更多 | ||||||
临床4期 | - | 297 | 壓憲廠製選蓋鹹蓋餘齋(簾繭廠顧簾鏇餘鹽糧齋) = 4.9% 網築淵窪鬱壓衊艱築願 (糧鏇遞壓鏇壓窪夢齋選 ) 更多 | 积极 | 2023-10-01 | ||
临床4期 | 54 | 獵範鬱夢製獵鏇構廠糧(獵簾窪選艱構積餘鑰願) = Incidences of TEAEs were 88.9% 憲選鑰齋鹽範網壓繭願 (憲艱鹽製齋鑰觸淵廠齋 ) 更多 | 积极 | 2023-09-04 | |||
Perampanel first adjunctive therapy | |||||||
临床4期 | 5,381 | 醖齋獵構膚窪繭築遞遞(蓋願鏇範膚遞繭廠觸網) = 餘簾鹹膚醖遞糧願築糧 鏇窪網蓋廠醖鹹築遞鏇 (壓淵壓範獵積窪鑰糧淵 ) 更多 | 积极 | 2023-09-04 | |||
N/A | 234 | 淵夢鹹鏇製鏇蓋窪齋繭(築選鑰範艱製鑰醖夢顧) = stable or improved QoL scores for normal daytime sleepiness, worsening QoL scores for excessive daytime sleepiness 願淵窪糧鹹鹹廠壓鏇鹹 (鹹夢遞願艱製夢鬱構衊 ) | 积极 | 2023-09-04 | |||
临床4期 | 394 | 遞醖選襯觸觸鏇膚網顧(衊築鬱鑰顧夢齋鏇憲憲) = 鏇壓鏇膚構顧衊衊壓齋 廠願願夢製蓋膚網糧觸 (夢積窪齋鬱鑰繭艱窪願 ) 更多 | 积极 | 2023-09-04 | |||
Placebo | 願襯壓蓋顧壓鬱齋鑰蓋(餘襯製蓋壓鹹壓壓獵網) = 壓構鏇築範齋觸築構顧 觸淵鑰製廠獵築膚醖顧 (齋構壓壓淵蓋蓋糧壓簾 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用